Viela Bio Inc., of Gaithersburg, Md., said it closed its IPO of 9.08 million shares, a total that includes 1.18 million shares sold from the exercise in full by the underwriters of their option to purchase additional shares, at $19 each. The gross proceeds were approximately $172.6 million.

Theratechnologies Inc., of Montreal, reported that for the third quarter ended Aug. 31, consolidated revenue for the three- and nine-month periods totaled $16.11 million and $46.8 million, respectively, compared to $13.52 million and $31.23 million, respectively, for the same periods last year, an increase of 19.1% and 49.9%. 

Kinoxis Therapeutics Pty Ltd., of Melbourne, Australia, received an NIH National Institute of Drug Abuse grant for $4.6 million to fund preclinical and clinical development of Kinoxis' lead compound, KNX-100, for treating opioid withdrawal. The funding is connected to achieving certain development milestones, as KNX-100 is in a phase I study in healthy volunteers.